Hepatocellular carcinoma(HCC),a common malignancy worldwide,still lacks effective clinical treatment.The study aimed to investigate the oncogenes that affect the progression of HCC and their possible mechanisms.In our...Hepatocellular carcinoma(HCC),a common malignancy worldwide,still lacks effective clinical treatment.The study aimed to investigate the oncogenes that affect the progression of HCC and their possible mechanisms.In our study,we initially confirmed a higher level of PRDX2 in the bile of HCC patients compared to those with choledocholithiasis by 2-DE,LC-MS,and ELISA.Subsequently,we demonstrated the high expression of peroxiredoxin 2(PRDX2)in HCC based on the TCGA database and clinical sample analysis.Furthermore,PRDX2 overexpression enhanced the viability of HCC cells.And PRDX2 silencing induced senescence of HCC cells.In vivo,knockdown of PRDX2 significantly reduced the weight of xenograft tumors.PRDX2 also was found to activate the Wnt/β-catenin pathway by inducingβ-catenin nuclear translocation.Consequently,we proved that silencing PRDX2 could inhibit proliferation and Wnt/β-catenin pathway while promoting senescence in HCC cells.展开更多
基金National Nature Science Foundation of China(Nos.81960118,81860115,81760116 and 82060116)Guizhou Science and Technology Project:Qiankehe Foundation(No.(2020)1Y300)+8 种基金Natural Science Foundation of Sichuan(No.2022NSFSC0837)Science and Technology Project of Chengdu(No.2022-YF05-01811-SN)Science and Technology Project of Guizhou Province(No.YQK(2023)032)Guizhou Medical University Doctoral Start-Up Fund(No.gyfybsky-2021-27)Guizhou Medical University Doctoral Start-Up Fund(No.gyfybsky-2021-26)Guizhou Science and Technology Department(No.(2019)1259)Guizhou Science and Technology Department Guizhou Science and Technology Platform Talents(No.(2017)5718)Science and Technology Fund of Guizhou Provincial Health Commission(No.gzwki2021-382)The Affiliated Hospital of Guizhou Medical University Excellent Reserve Talent in 2023(No.gyfyxkrc-2023-06).
文摘Hepatocellular carcinoma(HCC),a common malignancy worldwide,still lacks effective clinical treatment.The study aimed to investigate the oncogenes that affect the progression of HCC and their possible mechanisms.In our study,we initially confirmed a higher level of PRDX2 in the bile of HCC patients compared to those with choledocholithiasis by 2-DE,LC-MS,and ELISA.Subsequently,we demonstrated the high expression of peroxiredoxin 2(PRDX2)in HCC based on the TCGA database and clinical sample analysis.Furthermore,PRDX2 overexpression enhanced the viability of HCC cells.And PRDX2 silencing induced senescence of HCC cells.In vivo,knockdown of PRDX2 significantly reduced the weight of xenograft tumors.PRDX2 also was found to activate the Wnt/β-catenin pathway by inducingβ-catenin nuclear translocation.Consequently,we proved that silencing PRDX2 could inhibit proliferation and Wnt/β-catenin pathway while promoting senescence in HCC cells.
